Literature DB >> 900181

d-Norgestrel concentrations in maternal plasma, milk, and child plasma during administration of oral contraceptives to nursing women.

S Nilsson, K G Nygren, E D Johansson.   

Abstract

In order to correlate plasma and milk concentrations of d-norgestrel (d-Ng) in lactating women, three oral contraceptives, containing different amounts of this synthetic gestagen, were given to 15 fully lactating women, starting two months post partum. Plasma and milk samples were collected according to a special schedule. d-Ng concentrations in plasma and milk were measured by radioimmunoassay. When d-Ng was measured in milk, extraction was performed with petroleum ether and in the radioimmunoassay an internal standard was used. This method is evaluated in the present paper. The plasma: milk ratio of d-Ng was found to be about 100:15 and the amounts of d-Ng transferred with 600 ml. of milk per day were calculated to be 0.3 an 0.15 microgram with daily intakes of 250 and 150 microgram of d-Ng, respectively, corresponding to about 0.1 per cent of the given dose. When the women received 30 microgram of d-Ng daily, no d-Ng could be detected in the milk. In three of the breast-fed children the d-Ng concentration in plasma was measured. This concentration was found to be in the same range as would be expected after oral d-Ng medication to adults, allowing for body weight differences, indicating that d-Ng is metabolized and is not accumulated in the baby.

Entities:  

Keywords:  Biology; Clinical Research; Contraception; Contraceptive Agents, Female--administraction and dosage; Contraceptive Agents, Female--analysis; Contraceptive Agents, Female--side effects; Contraceptive Agents, Progestin--administraction and dosage; Contraceptive Agents, Progestin--analysis; Contraceptive Agents, Progestin--side effects; Contraceptive Agents--administraction and dosage; Contraceptive Agents--analysis; Contraceptive Agents--side effects; Contraceptive Methods--side effects; Evaluation; Examinations And Diagnoses; Family Planning; Hematological Effects; Hemic System; Laboratory Examinations And Diagnoses; Laboratory Procedures; Lactation; Levonorgestrel--administraction and dosage; Levonorgestrel--analysis; Levonorgestrel--side effects; Maternal Physiology; Oral Contraceptives--side effects; Physiology; Research Methodology

Mesh:

Substances:

Year:  1977        PMID: 900181     DOI: 10.1016/0002-9378(77)90741-4

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  7 in total

Review 1.  Clinical pharmacokinetics of oral contraceptive steroids.

Authors:  M L Orme; D J Back; A M Breckenridge
Journal:  Clin Pharmacokinet       Date:  1983 Mar-Apr       Impact factor: 6.447

Review 2.  Levonorgestrel. Clinical pharmacokinetics.

Authors:  K Fotherby
Journal:  Clin Pharmacokinet       Date:  1995-03       Impact factor: 6.447

Review 3.  Long acting contraceptives. Present status.

Authors:  G Benagiano; F M Primiero
Journal:  Drugs       Date:  1983-06       Impact factor: 9.546

Review 4.  Drugs in human milk. Clinical pharmacokinetic considerations.

Authors:  H C Atkinson; E J Begg; B A Darlow
Journal:  Clin Pharmacokinet       Date:  1988-04       Impact factor: 6.447

Review 5.  Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part I).

Authors:  J B Besunder; M D Reed; J L Blumer
Journal:  Clin Pharmacokinet       Date:  1988-04       Impact factor: 6.447

6.  A single-arm study to evaluate the transfer of drospirenone to breast milk after reaching steady state, following oral administration of 4 mg drospirenone in healthy lactating female volunteers.

Authors:  Dace Melka; Kalev Kask; Enrico Colli; Pedro-Antonio Regidor
Journal:  Womens Health (Lond)       Date:  2020 Jan-Dec

7.  Comparison of levonorgestrel level and creamatocrit in milk following immediate versus delayed postpartum placement of the levonorgestrel IUD.

Authors:  Niaree G Hopelian; Rebecca G Simmons; Jessica N Sanders; Katherine Ward; Sabrina Malone Jenkins; Eve Espey; David K Turok
Journal:  BMC Womens Health       Date:  2021-01-21       Impact factor: 2.809

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.